In the management of type 2 diabetes mellitus (T2DM), severalmolecular targets have been identified as key therapeutic focuses,including α-glucosidase, dipeptidyl peptidase-4 (DPP-4), peroxisomeproliferator-activated receptor gamma (PPARγ), and protein tyrosinephosphatase 1B (PTP1B).5,6 These targets represent promisingavenues for the development of more effective treatments aimed ataddressing the global burden of diabetes and its complications. This evidence concerns the gene PPARG and type 2 diabetes mellitus.